Aequus Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Doug Janzen

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.8yrs
Eigendom CEO	9.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Doug Janzen's beloning veranderd ten opzichte van Aequus Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CA$3m
Jun 30 2024	n/a	n/a	-CA$3m
Mar 31 2024	n/a	n/a	-CA$3m
Dec 31 2023	n/a	n/a	-CA$3m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$3m
Mar 31 2023	n/a	n/a	-CA$3m
Dec 31 2022	CA$206k	CA$206k	-CA$3m
Sep 30 2022	n/a	n/a	-CA$3m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$225k	CA$225k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$2m
Jun 30 2021	n/a	n/a	-CA$2m
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$212k	CA$212k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$2m
Jun 30 2020	n/a	n/a	-CA$2m
Mar 31 2020	n/a	n/a	-CA$3m
Dec 31 2019	CA$191k	CA$191k	-CA$3m
Sep 30 2019	n/a	n/a	-CA$3m
Jun 30 2019	n/a	n/a	-CA$3m
Mar 31 2019	n/a	n/a	-CA$3m
Dec 31 2018	CA$180k	CA$180k	-CA$3m
Sep 30 2018	n/a	n/a	-CA$3m
Jun 30 2018	n/a	n/a	-CA$3m
Mar 31 2018	n/a	n/a	-CA$4m
Dec 31 2017	CA$258k	CA$210k	-CA$4m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Doug redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Canadian markt.

Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Doug Janzen (55 yo)

11.8yrs

Tenure

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Douglas Janzen	Chairman	11.8yrs	geen gegevens	9.46% CA$ 62.8k
Marc Lustig	Independent Director	3.8yrs	CA$3.72k	5.21% CA$ 34.6k
Christopher Clark	Director	9.9yrs	CA$3.72k	geen gegevens
Iqbal Ahmed	Chairman of Strategic Advisory Board	6yrs	geen gegevens	geen gegevens
Anne Stevens	Director	9.9yrs	CA$3.72k	geen gegevens
Rosa Braga-Mele	Member of Strategic Advisory Board	6yrs	geen gegevens	geen gegevens
Vikram Lekhi	Member of Strategic Advisory Board	6yrs	geen gegevens	geen gegevens
Ken Patterson	Member of Strategic Advisory Board	6yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AQS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

Aequus Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 3Q 2022)

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Health Check: How Prudently Does Aequus Pharmaceuticals (CVE:AQS) Use Debt?

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Is Aequus Pharmaceuticals (CVE:AQS) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Chairman & CEO recently bought CA$73k worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Chairman recently bought CA$58k worth of stock

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Chairman exercised options to buy CA$328k worth of stock.

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

New 90-day high: CA$0.28

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

New 90-day high: CA$0.23

Is Aequus Pharmaceuticals (CVE:AQS) Using Too Much Debt?

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

Analyse CEO-vergoeding

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd